Welcome to the Fangzhou Inc. Investor Relations Portal
We are the largest online chronic disease management platform in China in terms of average MAU in 2023, according to CIC. We commenced our business with a focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases.
To address the needs of patients with chronic diseases for convenient and accessible medical care services, we provide comprehensive medical services and online retail pharmacy services through our Jianke Platform. Our comprehensive medical services include follow-up physician consultations and e-prescription services conducted by registered physicians and in-house medical professionals through our hospital-to-home (“H2H”) service platform. We also provide online retail pharmacy services, offering a wide range of pharmaceutical and healthcare products directly to our customers. Our comprehensive medical services and online retail pharmacy services are supported by our chronic disease management service center and robust pharmaceutical supply chain.
In addition, our platform’s large and active user base allows us to effectively connect and engage with doctors and patients, providing them targeted medical knowledge and content. By leveraging these powerful network effects, our platform provides pharmaceutical companies with customized content and marketing solutions to better inform physicians and patients about chronic disease conditions and treatment options, as well as increase disease awareness among the public.
As of December 31, 2023, our chronic disease management service platform had approximately 42.7 million registered users. For the year ended December 31, 2023, our Jianke Platform had an average of approximately 8.4 million monthly active users. As of December 31, 2023, the number of registered doctors on our H2H platform reached 212,892, and our registered doctors came from over 15,600 medical institutions, with approximately 58.8% of them working for Class Ⅲ hospitals, and approximately 38.4% of them had obtained a title of associate chief physician or above.
Leveraging our chronic disease management platform, we are dedicated to providing tailored medical care and precision medicine for a growing population of chronic disease patients, with a view towards extending our services to a wider range of disease areas.
Company Honors:
2023-the "Southern Tribute·Annual Craftsmanship Enterprise" by Southern Daily for the year 2023
2023-the information company under Fangzhou Jianke was honored "2023 Guangdong Specialized and Innovative Small-Medium Enterprise," " Guangzhou Outstanding Software Enterprise," and "2023 Guangdong Artificial Intelligence Influential List ·Technology Enterprise" among other titles
2022-recognized with the 2022 Comprehensive Health Quality Manufacturing Leadership Award at the 3rd International Quality Festival/2022 Global Consumer Leadership Summit
2022-elected as the List of Health Consumer Service Providers at the China International Consumer Products Expo - Global Healthcare Consumer Forum
2022-received the 2022 Digital Transformation Impetus Award at the 11th China Finance Summit
2021-awarded the 2021 Jinge Award—Internet Healthcare Innovative Award at the Healthcare Industry Insurance Summit